Valerio Therapeutics SA 2014 IR
The report highlights Onxeo's strategic progress in 2014 following the merger between BioAlliance Pharma and Topotarget to focus on orphan oncology drugs. Key achievements include receiving FDA approval for Beleodaq® to treat peripheral T-cell lymphoma and launching its commercialization in the US. Additionally, the company reported positive Phase II clinical trial results for Validive® and continued its Phase III trial for Livatag®. Onxeo also strengthened its financial position through a successful capital increase of over 40 million euros.
Company: Valerio Therapeutics SA
Sector: Professional & technical services
Country: France
Year: 2014
Type: IR
Pages: 254
Back to company
Valerio Therapeutics SA
Reference Document
The report highlights Onxeo's strategic progress in 2014 following the merger between BioAlliance Pharma and Topotarget to focus on orphan oncology drugs. Key achievements include receiving FDA approval for Beleodaq® to treat peripheral T-cell lymphoma and launching its commercialization in the US. Additionally, the company reported positive Phase II clinical trial results for Validive® and continued its Phase III trial for Livatag®. Onxeo also strengthened its financial position through a successful capital increase of over 40 million euros.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Jan 1, 2014 - Dec 31, 2014
Fiscal Year
2014
Published
Apr 14, 2015
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees